Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
26 Sep 2024
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
CAR-T - Choosing Wisely
BMC data: Transplant
Welcome & Inauguration
Reducing drug expenditures without harming patients
Health economics of Universal Health Coverage in India
Weaving in Choosing Wisely, Common Sense Oncology in all aspects of global health
About ecancer
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Highlights and analysis
The promise of CAR T cell therapy for multiple myeloma
Revolving door between the regulators and industry